FDA Approves Secuado for Adults With Schizophrenia

Noven Pharmaceuticals received the FDA’s approval for Secuado (asenapine) as the first transdermal patch to treat adults with schizophrenia.

The FDA approved it based on the results of a phase 3 trial in which the patch demonstrated significant improvement compared to a placebo.

Noven’s CEO Naruhito Higo said the company plans to launch the product on the U.S. market “as soon as possible” so schizophrenia patients have a transdermal delivery option for asenapine treatment.